Help Desk

860-305-6955

F.A.Q

Have questions? We’ve got answers. Browse our FAQs to learn more about who we are and what we do.

Help Center

Have a query? Please check this question and answers

Opioids are a class of drugs that include prescription pain relievers like oxycodone, hydrocodone, morphine, and fentanyl, as well as illegal drugs like heroin. They work by binding to receptors in the brain to reduce pain, but they also produce feelings of euphoria, which can lead to misuse and addiction.

The opioid epidemic refers to the rapid increase in the use of prescription and non-prescription opioid drugs in the U.S. and other countries. This crisis has led to a significant rise in addiction, overdose deaths, and public health challenges.

v

Phoenix PharmaLabs was founded by Dr. John Lawson, a medicinal chemist who first discovered a new family of opioid molecules during his time at the Stanford Research Institute (now SRI International). Years later, while working as a Visiting Scientist at Utah State University, he established the company in Utah to advance the development of these promising compounds.

You will just need to have the latest version of Elementor installed on your website to be able to use the HappyAddons.

Our mission is to transform lives by developing potent, safe, and non-addictive pain treatments. We are dedicated to advancing science-backed therapies that address the widespread challenges of pain, addiction, and PTSD with care, innovation, and integrity.

PPL-138 is being developed to treat pain, addiction, and post traumatic stress disorder (PTSD). 

Phoenix PharmaLabs is funded through a combination of competitive government grants and private investment. The company has received over $12 million in non-dilutive funding from the National Institutes of Health (NIH) and the Department of Defense (DoD), recognizing the scientific merit and potential impact of its compounds. This support has been supplemented by approximately $10 million in private equity investment, including a $2 million online public offering under SEC Rule CF that was oversubscribed. Phoenix is actively pursuing additional grant opportunities and private funding to support the continued development of its therapies.

The market opportunity for Phoenix PharmaLabs is substantial. The global opioid market is estimated at $30 billion and continues to grow. However, the potential for PPL-138 extends well beyond this, as millions of people worldwide suffer from severe pain without access to adequate treatment due to concerns about addiction. 

To get involved, email Bev Jedynak at [email protected] 

Mr. Crossman is responsible for the overall management of the Company and the creation, planning and execution of business and financial strategies and corporate development activities, including capital generation.
Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 500 level companies. He has a proven track record of successfully commercializing various emerging technologies including manufacturing and industrial systems, computer software, marine bioremediation, nanotechnology and life sciences.

Mr.Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets. As CEO of ISOPur Fluid Technologies, Crossman led the company from product introduction to global growth with expanding applications in multiple vertical markets. Important strategic alliances were developed with Siemens, BHP, Atlas Copco, Hess, Sanwa Shoko and others, creating a platform for continued strong growth.

The value of the founding shareholders’ common stock increased more than tenfold in less than three years under Crossman’s leadership. As CFO of Otis Elevator Company – Asia Pacific Operations, Crossman evaluated, negotiated and developed acquisitions, joint ventures and major capital investments in China, Japan, Korea, India, Southeast Asia, and Australia. Mr. Crossman contributed to profit growth of 20% per year and market share gains of 1% per year in this mature multi-billion dollar operation spanning 23 countries, despite aggressive competition from large Asian conglomerates. The joint ventures that he helped developed in China are among the most profitable operations of United Technologies Corp today. Bill holds a BS degree from the U.S. Merchant Marine Academy at Kings Point and a MBA from the Haas School of Business at the University of California – Berkeley.